

CLAIMS

1. (cancelled).

2. (cancelled)

3. (currently amended) ~~The isolated anti-hFasL human antibody, or antigen-binding portion thereof, of Claim 2~~ An isolated anti-hFasL human antibody, or antigen-binding portion thereof, comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises the amino acid sequence a polypeptide with the sequence shown in SEQ ID NO:2 and the HCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 10 and SEQ ID NO: 18.

4. (currently amended) The isolated anti-hFasL human antibody, or antigen-binding portion thereof, of Claim 3 ~~[[2]]~~, wherein the LCVR comprises the amino acid sequence shown in SEQ ID NO:2 and wherein the HCVR comprises the amino acid sequence shown in SEQ ID NO:10.

5. (currently amended) The isolated anti-hFasL human antibody, or antigen-binding portion thereof, of Claim 4 ~~[[2]]~~, wherein the LCVR comprises the amino acid sequence shown in SEQ ID NO:2 and wherein the HCVR comprises the amino acid sequence shown in SEQ ID NO: 18.

6-18 (cancelled)

4. 19. (currently amended) The isolated antibody of Claim 3 ~~[[1]]~~ which has an IgG 1 heavy chain constant region.

5. 20. (currently amended) The isolated antibody of Claim 3 ~~[[1]]~~ which has an IgG4 heavy chain constant region.

- 6 ~~21~~ (currently amended) The isolated antigen-binding portion of Claim ~~2~~ <sup>1</sup> ~~[[1]]~~ which is a Fab fragment.
- 7 ~~22~~ (currently amended) The isolated antigen-binding portion of Claim ~~2~~ <sup>1</sup> ~~[[1]]~~ which is a F(ab')<sub>2</sub> fragment.
- 8 ~~23~~ (currently amended) The isolated antigen-binding portion of Claim ~~2~~ <sup>1</sup> ~~[[1]]~~ which is a single chain Fv fragment.
24. (withdrawn) An isolated nucleic acid molecule comprising a polynucleotide encoding an anti-hFasL human antibody, or an antigen-binding portion thereof, of Claim 1.
25. (withdrawn) A vector comprising the nucleic acid molecule of Claim 24.
26. (withdrawn) The vector of Claim 25, wherein the vector is an expression vector.
27. (withdrawn) A host cell comprising the vector of Claim 25.
- 9 ~~28~~ (currently amended) A method for inhibiting hFasL activity comprising contacting hFasL with the antibody or antigen-binding portion thereof of Claim ~~2~~ <sup>1</sup> ~~[[1]]~~.
- 10 ~~29~~ (currently amended) A pharmaceutical composition comprising the antibody, or antigen-binding portion thereof, of Claim ~~2~~ <sup>1</sup> ~~[[1]]~~ and a pharmaceutically acceptable carrier.
30. (withdrawn) A method for inhibiting FasL activity in a subject in need thereof comprising administering to said subject the pharmaceutical composition of Claim 29.
31. (withdrawn) A method of treating or preventing a disorder in which FasL activity is detrimental comprising administering to a subject in need thereof the pharmaceutical

composition of Claim 29.

32. (withdrawn) The method of Claim 31 wherein the disorder is selected from the group consisting of systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute respiratory distress syndrome, severe sepsis, trauma, graft-versus-host disease, organ rejection associated with organ transplant, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, acute myocardial infarction, cardiomyopathy, cardiac reperfusion injury, diabetes, cancers which express FasL as a mechanism of evading the immune response, human immunodeficiency virus, influenza virus, hepatic disorders including but not limited to fulminant viral hepatitis B or C, chronic hepatitis C virus, chronic hepatitis B virus, alcoholic hepatitis, hepatic cirrhosis; and renal disorders including, but not limited to acute renal disease, chronic renal disease, and diabetic nephropathy.

33. (withdrawn) Use of the antibody or fragment of any one of Claims 1-23 in the treatment of a disorder to neutralize FasL activity.

34. (withdrawn) The use of Claim 33 wherein the disorder is selected from the group consisting of systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, acute respiratory distress syndrome, severe sepsis, trauma, graft-versus-host disease, organ rejection associated with organ transplant, multiple sclerosis, idiopathic pulmonary fibrosis, osteoarthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, acute myocardial infarction, cardiomyopathy, cardiac reperfusion injury, diabetes, cancer, human immunodeficiency virus, influenza virus, hepatic disorders including, but not limited to, fulminant viral hepatitis B or C, chronic hepatitis C virus, chronic hepatitis B virus, alcoholic hepatitis, and hepatic cirrhosis; and renal disorders.

35-40. (cancelled)

41. (new) A hybridoma selected from the group consisting of the hybridoma deposited as ATCC PTA-4017 and the hybridoma deposited as ATCC PTA-4018.